Trazodone Side Effects
Brand Names: Desyrel
Please note - some side effects for Trazodone may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).
|
For the consumer For the professional
|
|
Side Effects of Trazodone - for the consumer
Trazodone
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome when using Trazodone:
Seek medical attention right away if any of these SEVERE side effects occur when using Trazodone:Blurred vision; constipation; decreased appetite; dizziness; drowsiness; dry mouth; general body discomfort; headache; incoordination; light-headedness; muscle aches/pains; nausea; nervousness; sleeplessness; stomach pain; stuffy nose; swelling of the skin; tiredness; tremors.
TopSevere allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); blood in urine; chest pain; fainting; hallucinations; irregular heartbeat; light-headedness when rising from a lying or seated position; prolonged, inappropriate, or painful erections; seizures; shortness of breath; stroke; vomiting.
For the professional
Trazodone
Because the frequency of adverse drug effects is affected by diverse factors (e.g., drug dose, method of detection, physician judgment, disease under treatment, etc.) a single meaningful estimate of adverse event incidence is difficult to obtain. This problem is illustrated by the variation in adverse event incidence observed and reported from the inpatients and outpatients treated with Trazodone hydrochloride. It is impossible to determine precisely what accounts for the differences observed.
Clinical Trial Reports
The table below is presented solely to indicate the relative frequency of adverse events reported in representative controlled clinical studies conducted to evaluate the safety and efficacy of Trazodone hydrochloride.
The figures cited cannot be used to predict precisely the incidence of untoward events in the course of usual medical practice where patient characteristics and other factors often differ from those which prevailed in the clinical trials. These incidence figures, also, cannot be compared with those obtained from other clinical studies involving related drug products and placebo as each group of drug trials is conducted under a different set of conditions.
| Inpts. | Outpts. | |||||
| T | P | T | P | |||
| Number of Patients | 142 | 95 | 157 | 158 | ||
| T = Trazodone HCl P = Placebo | ||||||
| % of Patients Reporting | ||||||
| Allergic | ||||||
| Skin Condition/Edema | 2.8 | 1.1 | 7.0 | 1.3 | ||
| Autonomic | ||||||
| Blurred Vision | 6.3 | 4.2 | 14.7 | 3.8 | ||
| Constipation | 7.0 | 4.2 | 7.6 | 5.7 | ||
| Dry Mouth | 14.8 | 8.4 | 33.8 | 20.3 | ||
| Cardiovascular | ||||||
| Hypertension | 2.1 | 1.1 | 1.3 | * | ||
| Hypotension | 7.0 | 1.1 | 3.8 | 0.0 | ||
| Shortness of Breath | * | 1.1 | 1.3 | 0.0 | ||
| Syncope | 2.8 | 2.1 | 4.5 | 1.3 | ||
| Tachycardia/Palpitations | 0.0 | 0.0 | 7.0 | 7.0 | ||
| CNS | ||||||
| Anger/Hostility | 3.5 | 6.3 | 1.3 | 2.5 | ||
| Confusion | 4.9 | 0.0 | 5.7 | 7.6 | ||
| Decreased Concentration | 2.8 | 2.1 | 1.3 | 0.0 | ||
| Disorientation | 2.1 | 0.0 | * | 0.0 | ||
| Dizziness/Lightheadedness | 19.7 | 5.3 | 28.0 | 15.2 | ||
| Drowsiness | 23.9 | 6.3 | 40.8 | 19.6 | ||
| Excitement | 1.4 | 1.1 | 5.1 | 5.7 | ||
| Fatigue | 11.3 | 4.2 | 5.7 | 2.5 | ||
| Headache | 9.9 | 5.3 | 19.8 | 15.8 | ||
| Insomnia | 9.9 | 10.5 | 6.4 | 12.0 | ||
| Impaired Memory | 1.4 | 0.0 | * | * | ||
| Nervousness | 14.8 | 10.5 | 6.4 | 8.2 | ||
| Gastrointestinal | ||||||
| Abdominal/Gastric Disorder | 3.5 | 4.2 | 5.7 | 4.4 | ||
| Bad Taste in Mouth | 1.4 | 0.0 | 0.0 | 0.0 | ||
| Diarrhea | 0.0 | 1.1 | 4.5 | 1.9 | ||
| Nausea/Vomiting | 9.9 | 1.1 | 12.7 | 9.5 | ||
| Musculoskeletal | ||||||
| Musculoskeletal Aches/Pains | 5.6 | 3.2 | 5.1 | 2.5 | ||
| Neurological | ||||||
| Incoordination | 4.9 | 0.0 | 1.9 | 0.0 | ||
| Paresthesia | 1.4 | 0.0 | 0.0 | * | ||
| Tremors | 2.8 | 1.1 | 5.1 | 3.8 | ||
| Sexual Function | ||||||
| Decreased Libido | * | 1.1 | 1.3 | * | ||
| Other | ||||||
| Decreased Appetite | 3.5 | 5.3 | 0.0 | * | ||
| Eyes Red/Tired/Itching | 2.8 | 0.0 | 0.0 | 0.0 | ||
| Head Full-Heavy | 2.8 | 0.0 | 0.0 | 0.0 | ||
| Malaise | 2.8 | 0.0 | 0.0 | 0.0 | ||
| Nasal/Sinus Congestion | 2.8 | 0.0 | 5.7 | 3.2 | ||
| Nightmares/Vivid Dreams | * | 1.1 | 5.1 | 5.7 | ||
| Sweating/Clamminess | 1.4 | 1.1 | * | * | ||
| Tinnitus | 1.4 | 0.0 | 0.0 | * | ||
| Weight Gain | 1.4 | 0.0 | 4.5 | 1.9 | ||
| Weight Loss | * | 3.2 | 5.7 | 2.5 | ||
| *Incidence less than 1%. | ||||||
Occasional sinus bradycardia has occurred in long-term studies.
In addition to the relatively common (i.e., greater than 1%) untoward events enumerated above, the following adverse events have been reported to occur in association with the use of Trazodone hydrochloride in the controlled clinical studies: akathisia, allergic reaction, anemia, chest pain, delayed urine flow, early menses, flatulence, hallucinations/delusions, hematuria, hypersalivation, hypomania, impaired speech, impotence, increased appetite, increased libido, increased urinary frequency, missed periods, muscle twitches, numbness, and retrograde ejaculation.
Postintroduction Reports
Although the following adverse reactions have been reported in Trazodone hydrochloride users, the causal association has neither been confirmed nor refuted.
Voluntary reports received since market introduction include the following: abnormal dreams, agitation, alopecia, anxiety, aphasia, apnea, ataxia, breast enlargement or engorgement, cardiospasm, cerebrovascular accident, chills, cholestasis, clitorism, congestive heart failure, diplopia, edema, extrapyramidal symptoms, grand mal seizures, hallucinations, hemolytic anemia, hirsutism, hyperbilirubinemia, increased amylase, increased salivation, insomnia, leukocytosis, leukonychia, jaundice, lactation, liver enzyme alterations, methemoglobinemia, nausea/vomiting (most frequently), paresthesia, paranoid reaction, priapism, pruritus, psoriasis, psychosis, rash, stupor, inappropriate ADH syndrome, tardive dyskinesia, unexplained death, urinary incontinence, urinary retention, urticaria, vasodilation, vertigo and weakness.
Cardiovascular system effects which have been reported include the following: conduction block, orthostatic hypotension and syncope, palpitations, bradycardia, atrial fibrillation, myocardial infarction, cardiac arrest, arrhythmia, and ventricular ectopic activity, including ventricular tachycardia.
TopTrazodone Tablets
Because the frequency of adverse drug effects is affected by diverse factors (e.g., drug dose, method of detection, physician judgement, disease under treatment, etc.) a single meaningful estimate of adverse event incidence is difficult to obtain. This problem is illustrated by the variation in adverse event incidence observed and reported from the inpatients and outpatients treated with Trazodone hydrochloride. It is impossible to determine precisely what accounts for the differences observed.
Clinical Trial Reports:
The table below is presented solely to indicate the relative frequency of adverse events reported in representative controlled clinical studies conducted to evaluate the safety and efficacy of Trazodone hydrochloride.
The figures cited cannot be used to predict concisely the incidence of untoward events in the course of usual medical practice where patient characteristics and other factors often differ from those which prevailed in the clinical trials. These incidence figures, also, cannot be compared with those obtained from other clinical studies involving related drug products and placebo as each group of drug trials is conducted under a different set of conditions.
| *Incidence less than 1% T = Trazodone Hydrochloride P = Placebo | ||||
| Inpts. | Outpts. | |||
| T | P | T | P | |
| Number of Patients | 142 | 95 | 157 | 158 |
| % of Patients Reporting | ||||
| Allergic | ||||
| Skin Condition/Edema | 2.8 | 1.1 | 7.0 | 1.3 |
| Autonomic | ||||
| Blurred Vision | 6.3 | 4.2 | 14.7 | 3.8 |
| Constipation | 7.0 | 4.2 | 7.6 | 5.7 |
| Dry Mouth | 14.8 | 8.4 | 33.8 | 20.3 |
| Cardiovascular | ||||
| Hypertension | 2.1 | 1.1 | 1.3 | * |
| Hypotension | 7.0 | 1.1 | 3.8 | 0.0 |
| Shortness of Breath | * | 1.1 | 1.3 | 0.0 |
| Syncope | 2.8 | 2.1 | 4.5 | 1.3 |
| Tachycardia/ Palpitations | 0.0 | 0.0 | 7.0 | 7.0 |
| CNS | ||||
| Anger/Hostility | 3.5 | 6.3 | 1.3 | 2.5 |
| Confusion | 4.9 | 0.0 | 5.7 | 7.6 |
| Decreased Concentration | 2.8 | 2.1 | 1.3 | 0.0 |
| Disorientation | 2.1 | 0.0 | * | 0.0 |
| Dizziness/Light-headedness | 19.7 | 5.3 | 28.0 | 15.2 |
| Drowsiness | 23.9 | 6.3 | 40.8 | 19.6 |
| Excitement | 1.4 | 1.1 | 5.1 | 5.7 |
| Fatigue | 11.3 | 4.2 | 5.7 | 2.5 |
| Headache | 9.9 | 5.3 | 19.8 | 15.8 |
| Insomnia | 9.9 | 10.5 | 6.4 | 12.0 |
| Impaired Memory | 1.4 | 0.0 | * | * |
| Nervousness | 14.8 | 10.5 | 6.4 | 8.2 |
| Gastrointestinal | ||||
| Abdominal/Gastric Disorder | 3.5 | 4.2 | 5.7 | 4.4 |
| Bad Taste in Mouth | 1.4 | 0.0 | 0.0 | 0.0 |
| Diarrhea | 0.0 | 1.1 | 4.5 | 1.9 |
| Nausea/Vomiting | 9.9 | 1.1 | 12.7 | 9.5 |
| Musculoskeletal | ||||
| Musculoskeletal Aches/Pains | 5.6 | 3.2 | 5.1 | 2.5 |
| Neurological | ||||
| Incoordination | 4.9 | 0.0 | 1.9 | 0.0 |
| Paresthesia | 1.4 | 0.0 | 0.0 | * |
| Tremors | 2.8 | 1.1 | 5.1 | 3.8 |
| Sexual Function | ||||
| Decreased Libido | * | 1.1 | 1.3 | * |
| Other | ||||
| Decreased Appetite | 3.5 | 5.3 | 0.0 | * |
| Eyes Red/Tired/Itching | 2.8 | 0.0 | 0.0 | 0.0 |
| Head Full-Heavy | 2.8 | 0.0 | 0.0 | 0.0 |
| Malaise | 2.8 | 0.0 | 0.0 | 0.0 |
| Nasal/Sinus Congestion | 2.8 | 0.0 | 5.7 | 3.2 |
| Nightmares/Vivid Dreams | * | 1.1 | 5.1 | 5.7 |
| Sweating/Clamminess | 1.4 | 1.1 | * | * |
| Tinnitus | 1.4 | 0.0 | 0.0 | * |
| Weight Gain | 1.4 | 0.0 | 4.5 | 1.9 |
| Weight Loss | * | 3.2 | 5.7 | 2.5 |
Occasional sinus bradycardia has occurred in long-term studies.
In addition to the relatively common (i.e., greater than 1%) untoward events enumerated above, the following adverse events have been reported to occur in association with the use of Trazodone hydrochloride in the controlled clinical studies: akathisia, allergic reaction, anemia, chest pain, delayed urine flow, early menses, flatulence, hallucinations/delusions, hematuria, hyper-salivation, hypomania, impaired speech, impotence, increased appetite, increased libido, increased urinary frequency, missed periods, muscle twitches, numbness, and retrograde ejaculation.
Postintroduction Reports:
Although the following adverse reactions have been reported in Trazodone hydrochloride users, the causal association has neither been confirmed nor refuted.
Voluntary reports received since market introduction include the following: abnormal dreams, agitation, alopecia, anxiety, aphasia, apnea, ataxia, breast enlargement or engorgement, cardiospasm, cerebrovascular accident, chills, cholestatis, clitorism, congestive heart failure, diplopia, edema, extrapyramidal symptoms, grand mal seizures, hallucinations, hemolytic anemia, hirsutism, hyperbilirubinemia, increased amylase, increased salivation, insomnia, leukocytosis, leukonychia, jaundice, lactation, liver enzyme alterations, methemoglobinemia, nausea/vomiting (most frequently), paresthesia, paranoid reaction, priapism, pruritus, psoriasis, psychosis, rash, stupor, inappropriate ADH syndrome, tardive dyskinesia, unexplained death, urinary incontinence, urinary retention, urticaria, vasodilation, vertigo, and weakness.
Cardiovascular system effects which have been reported include the following: conduction block, orthostatic hypotension and syncope, palpitations, bradycardia, atrial fibrillation, myocardial infarction, cardiac arrest, arrhythmia, and ventricular ectopic activity, including ventricular tachycardia.
TopMore resources:
Trazodone - Includes detailed dosage instructions.
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.




